“The acquisition of Andrew Alliance broadens our technology portfolio to include advanced robotics and software that will positively impact our customers’ workflows across pharmaceuticals, life sciences and materials science markets,” commented Chris O’Connell, Chairman and Chief Executive Officer of Waters Corporation. “This move also demonstrates Waters’ commitment to deploy capital to growth-oriented acquisitions that reinforce our specialty strategy and enhance our core business.”
“We are excited to announce this strategic relationship with Andrew Alliance that will make it much easier for researchers to take greater advantage of the wide range of cutting-edge consumables that we supply to the life science industry,” said Tracy Andrews, Senior Product Manager of Brooks Life Sciences 4titude range. “This means that researchers will be able to more easily, and quickly, set up their liquid handling workflows in OneLab, be they for PCR, NGS or imaging, speeding up both their research and their ability to disseminate the work of other research groups.” “What makes this especially powerful, if that these protocols can then be executed on either Andrew Alliance’s automated liquid handling solutions, increasing productivity and reducing the risk of error.”
Leaders in fields ranging from biomedical research to social science have said it again and again: replication matters, and so does sharing protocols.  The importance of repeating experiments is central to the career of the scientist.  Indeed, it is absolutely crucial, be it for a research publication or for a patent application.  In order for a finding to have any significance at all, it needs to be ‘true’ more than the one time that it was done by the original research group.  If not, we have to attribute it to either serendipity, sloppy dissemination or, rarely, fraud.  A major result may depend on a subtlety in how the experiment was conducted that was neither communicated via a research or indeed, conference paper.